论文部分内容阅读
我院１９７８年以来，收治８１例ＡＭＬ患者，应用剂量偏小的联合化疗，同时常规进行脑膜白血病防治及非特异性免疫疗法，取得较好疗效和长期生存率，本组总缓解率５９．６８％，ＣＲ４５．１６％１ＰＲ１４．５２％。获ＣＲ者１、３、５和１０年生存率分别为８４％，２８％、１６％和４％。生存曲线显示ＣＲ后第四年曲线趋平坦，复发死亡大大减少。本文分析预后危险因素，表明年龄大和脾肿大预后不良（Ｐ值分别＜０．０１和＜０．０５）．生存期与缓解持续时间有明显关系，坚持５年维持和强化治疗仍属必要。
Since 1978 in our hospital, 81 patients with AML have been treated with a combination of small doses of chemotherapy, routine meningeal leukemia prevention and non-specific immunotherapy, and achieved good efficacy and long-term survival rate. The total response rate in this group was 59.68%. , CR45.16%1PR14.52%. The 1-, 3-, 5-, and 10-year survival rates for CR patients were 84%, 28%, 16%, and 4%, respectively. The survival curve shows that the fourth year after CR curve flattened and relapses were greatly reduced. This article analyzes prognostic risk factors, indicating that older age and splenomegaly have a poor prognosis (P values <0.01 and <0.05, respectively). There is a clear relationship between survival time and duration of remission. It is still necessary to maintain and strengthen treatment for 5 years.